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Thymic tumors are a rare entity with a peculiar behavior 
ranging from indolent neoplasms to aggressive cancers (1). 
Complete surgical resection is advocated as the gold 
standard when feasible (2); chemotherapy and radiotherapy 
can be administered as an induction at advanced stages 
unsuitable for complete resection (3) or as adjuvant 
treatment in case of advanced pathological stages, aggressive 
histologies (3,4) or R+ resection. For a long time, because of 
the median position of the thymus within the mediastinum, 
the resection of thymic tumors has been almost always 
performed through a median access (complete sternotomy, 
sternal split, cervicotomy) and, in exceptional cases, by 
clamshell or combined incisions. Thymectomy included 
complete removal of thymus and the perithymic tissue. 
During the last ten years, due technological improvements, 
new trends in surgical management of thymic tumors have 
been proposed; particularly, the impressive impulse towards 
minimally invasive surgery is worldwide changing the 
historical dogmas concerning thymic surgery. 
As reported in the exhaustive review by the group 
of Enrico Ruffini (5) several aspects about surgical 
management are now challenging and changing our 
historical view. They identified four key points currently 
under debate: (I) the role of minimally invasive surgery, 
(II) the role of lymph node dissection, (III) the extension 
of resection in case of non-myasthenic thymoma and (IV) 
the management of locally-advanced thymic tumors with 
pleural involvement. Although all these issues deserve 
critical discussion and analysis, two of them (role of 
lymph node dissection and extension of resection) require 
further comments. In fact, up to now the role and limits of 
minimally invasive surgery is clear enough in all fields of 
thoracic surgery as well as the management of borderline 
cases as patients with locally advanced tumors. On the other 
hand, the usefulness of lymph node staging for thymic 
tumors and the possibility to perform partial thymectomy 
are new concepts that has not yet validated and accepted. 
The Masaoka-Koga staging system has been one of the 
cornerstones in the management of thymic tumors (6). The 
strong efforts of the International Thymic Malignancies 
Interest Group (ITMIG) in collaboration with other 
international societies produced a new staging system as 
part of the 8th TNM edition (7,8) with huge differences 
compared to the previous classification concerning lymph 
node dissection; particularly, surgeons might identify, 
sample or remove anterior perithymic lymph nodes (N1) 
and deep intrathoracic or cervical stations (N2). The 
review reports single center retrospective experiences (9) 
and retrospective studies with data extrapolated from large 
national database (10) that have been useful to rewrite the 
staging system. In all of them it is clearly shown that N+ 
is an independent prognostic factor affecting prognosis; 
this variable is strongly associated with the diameter of 
the tumor and aggressive histologies. In fact, as part of 
their review the authors report the ESMO guidelines, 
suggesting lymphadenectomy for thymomas invading 
neighboring structures, thymic carcinoma or NETT. 
The question is: how does management of these patients 
change after lymph node dissection? We all know that in 
lung cancer patients the presence of N+ disease encourages 
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administration of adjuvant therapy independently from 
histology or T status. For thymic tumors it looks like this 
is not the case since patients with invasive tumors or more 
aggressive histologies already receive adjuvant therapy. 
Thus, we probably need more specific and prospective data 
to validate this procedure, also considering that lymph node 
dissection dilates operative time and can negatively affect 
the postoperative course.
The second point is related to the best surgical treatment 
for non-myasthenic thymoma patients. Historically, based 
on oncological reasons, thymectomy consisted in the en-
bloc removal of thymic tumor and thymic gland; recently, a 
new approach has been proposed called “thymomectomy” 
or limited thymectomy, performing only the resection of 
thymoma sometimes associated with removal of part of the 
thymus. The promoters of this “philosophy” particularly 
suitable for thoracoscopic resections consider this 
procedure oncologically adequate at early stages (11,12); 
in these reports it is underlined that in patients treated 
by total thymectomy or thymomectomy the disease-free 
survival and the rate of new onset of myasthenia gravis 
are similar. Furthermore, some authors postulate that the 
preservation of thymus could be useful in the remaining 
life as immunologic help in case of future diseases (13). 
However, there are some critical points: first of all, the 
possibility of a potentially incomplete resection in case of 
limited thymectomy is higher, particularly at stage II, as 
shown in a study from the Chinese Alliance for Research 
in Thymoma (2.9% vs. 14.5%) (14). Furthermore, it has 
been well described that also at early stages thymoma could 
present multiple nodules in the remaining gland (15) or 
show different histologies (also more aggressive) in a single 
nodule (16) that could negatively affect prognosis due to 
an increased recurrence rate. In addition, follow-up of 
these patients must obviously be longer and, once again, we 
need prospective studies. Finally, we would like to remark 
a little but substantial “mistake” in the review paper that 
could generate misunderstanding: the authors report that a 
multicenter study from the Korean Association for Research 
on Thymoma showed a lower incidence of postoperative 
complications after limited thymectomy when compared 
to complete thymectomy. This is not true. In the original 
paper (12) it is clearly written in the text and reported in 
a table that postoperative complications are similar (not 
statistically different): 5% for limited thymectomy and 3.5% 
for complete thymectomy. 
In conclusion, we are living an exceptional wind of 
change in the surgical treatment of thymic tumors; however, 
we must always follow basic surgical principles and 
oncological rules to avoid misunderstanding with potential 
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